Vorinostat for graft-versus-host disease prevention in pediatric and young adult patients with hematologic malignancies

Authors:

Abstract
BACKGROUND: This prospective, single-arm, multicenter phase I/II trial evaluated vorinostat added to standard graft-versus-host disease (GVHD) prophylaxis in pediatric, adolescent, and young adult (AYA) patients undergoing allogeneic hematopoietic cell transplantation (HCT) from HLA-matched related, HLA-matched unrelated, and haploidentical donors. METHODS: Patients aged 3–39 years received twice-daily vorinostat with tacrolimus/methotrexate after HLA-matched HCT from day –10 to +30, or with posttransplant cyclophosphamide/tacrolimus/mycophenolate mofetil after haploidentical HCT from day +5 to +30. The primary endpoint was cumulative incidence of grade 2–4 acute GVHD by day +100. All outcomes were based on intention-to-treat analysis. RESULTS: Forty-three patients were enrolled; median age was 19 years, with 74% receiving HLA-matched and 26% haploidentical HCT. The recommended phase II dose was 60 mg/m 2 twice daily. No dose-limiting toxicities, unexpected vorinostat-related serious adverse events, or primary graft failures occurred. Median neutrophil and platelet recovery occurred at 14 and 18 days, respectively. Day +100 grade 2–4 and 3–4 acute GVHD were 14% (95% CI, 5.6%–26%) and 4.7% (95% CI, 0.83%–14%), respectively. One-year overall survival was 88.4% (95% CI, 79.3%–98.5%), relapse 14% (95% CI, 5.6%–26%), nonrelapse mortality 4.7% (95% CI, 0.8%–14%), and GVHD-free/relapse-free survival 55.8% (95% CI, 42.8%–72.8%). Correlative studies demonstrated on-target HDAC activity, with increased histone. RESULTS: Forty-three patients were enrolled; median age was 19 years, with 74% receiving HLA-matched and 26% haploidentical HCT. The recommended phase II dose was 60 mg/m 2 twice daily. No dose-limiting toxicities, unexpected vorinostat-related serious adverse events, or primary graft failures occurred. Median neutrophil and platelet recovery occurred at 14 and 18 acetylation and lower proinflammatory cytokines. CONCLUSION: These findings support randomized evaluation of vorinostat-based GVHD prophylaxis in pediatric and AYA HCT. TRIAL REGISTRY: ClinicalTrials.gov NCT03842696. FUNDING: NIH grants 1R01CA249211, UG1HL069330, 1K24HL156896, and NHLBI Training Grant T32HL007622-36.
Funding Information
  • National Institutes of Health (T32HL007622-36,1R01CA249211,UG1HL069330,1K24HL156896)

This publication has 41 references indexed in Scilit: